TICKERNERD
Menu
OCGNOCGNHealthcare · Biotechnology

OCGN Stock Forecast: Ocugen, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$1.36
−2.16% on the day

The 6 Wall Street analysts covering Ocugen, Inc. hold a median 12-month price target of $11 — +672.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$471.4M
Ticker Nerd rank
26 / 100
Median analyst target
$11
Analysts covering
6
Revenue$1.5M+8.4% y/y
Operating income−$16.4M
Net income−$24.9M
Free cash flow−$12.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.1%
1M
+12.4%
YTD
+0.7%
1Y
+34.7%
From 52W high
−45.2%
From 52W low
+33.3%
$1.02
$2.48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OCGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ocugen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
26 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
73
Volatility
66
Momentum
56
Size
55
Value
54
Revisions
38
Growth
30
Quality
10
Issuance
9

Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OCGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OCGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26OCGNHigh $22Median $11Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $8Median $11High $22

The green dot is the last close — the median target sits +672.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 May 2026Canaccord GenuityMaintainsBuy$12 → $11
25 Mar 2026Chardan CapitalMaintainsBuy—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
17 Mar 2026Canaccord GenuityInitiatesBuy—
11 Mar 2026OppenheimerInitiatesOutperform—
5 Mar 2026Chardan CapitalMaintainsBuy—
20 Jan 2026Chardan CapitalMaintainsBuy—
19 Sept 2025Chardan CapitalMaintainsBuy—
4 Aug 2025Chardan CapitalMaintainsBuy—
24 June 2025Chardan CapitalMaintainsBuy—
24 June 2025HC Wainwright & Co.ReiteratesBuy—
12 May 2025Chardan CapitalMaintainsBuy—
12 May 2025HC Wainwright & Co.MaintainsBuy—
6 Mar 2025Chardan CapitalMaintainsBuy—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Feb 2025Chardan CapitalMaintainsBuy—
13 Feb 2025HC Wainwright & Co.MaintainsBuy—
23 Jan 2025Chardan CapitalMaintainsBuy—
13 Jan 2025HC Wainwright & Co.ReiteratesBuy—
18 Nov 2024Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OCGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OCGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Ocugen, Inc. returned +34.7% against +19.6% for the S&P 500, dividends included.

OCGN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26OCGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OCGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
4
Fundamentals

Ocugen, Inc. (OCGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.1×

Cheaper than 91% of US stocks

Price / sales
102.9×

Cheaper than 4% of US stocks

Price / book
−28.6×

Cheaper than 99% of US stocks

EV / EBITDA
−6.8×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
8.4%

Higher than 48% of US stocks

Earnings growth (YoY)
8.4%

Higher than 46% of US stocks

Gross margin
—
Operating margin
−1105.1%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
557.7%

Higher than 99% of US stocks

Return on assets
−48.4%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ocugen, Inc. (OCGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ocugen, Inc. has a market value of $471.4M and an enterprise value of $459.3M.

  • Revenue in the twelve months to 30 June 2026: $4.6M. The latest quarter grew 8.4% year on year.

  • Net income over the same four quarters: −$81.8M, a −1786.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.25.

  • Free cash flow in the twelve months to 30 June 2026: −$61.0M.

  • Shares outstanding: 339.0M.

  • Trailing P/E: −6.1×; forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Ocugen, Inc. employs 116 people — $39K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

OCGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OCGNOcugen, Inc.$471.4M
26
PBYIPuma Biotechnology, Inc.$470.2M
92
QTTBQ32 Bio, Inc.$475.3M
86
EDITEditas Medicine, Inc.$477.3M
76
DNAGinkgo Bioworks Holdings, Inc.$479.3M
51
RLMDRelmada Therapeutics, Inc.$485.6M
68
PROKProKidney Corp.$485.9M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ocugen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OCGN news & analysis

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts

MarketBeat · 16 Aug 2026neutral

Ocugen is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration. CEO Shankar Musunuri discussed pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy during a Canaccord discussion.

Why it matters — OCGN watchers would care because the company is advancing multiple pivotal-stage gene therapy programs for retinal diseases, which represent the core of its pipeline and key upcoming data events.

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Zacks Investment Research · 7 Aug 2026negative

Ocugen reported a larger-than-expected second-quarter loss, driven by increased research and development spending as it progresses its late-stage gene therapy programs.

Why it matters — The earnings miss and rising R&D costs may concern investors, though the company extended its cash runway into 2028, providing some financial flexibility as it advances key programs.

Ocugen Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Ocugen reported progress in its second quarter across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and receipt of a Regenerative Medicine Advanced Therapy (RMAT) designation for the program.

Why it matters — OCGN watchers would care because FDA clearance to advance OCU410 into a Phase III trial and the RMAT designation represent meaningful regulatory milestones for a key late-stage pipeline candidate.

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published a transcript of Ocugen, Inc.'s Q2 2026 earnings call, covering the company's financial results and management commentary for the quarter.

Why it matters — The earnings call transcript provides OCGN watchers with direct insight into the company's recent performance and strategic updates.

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 6 Aug 2026negative

Ocugen reported a quarterly loss of $0.07 per share for Q2, which came in wider than the Zacks Consensus Estimate of a $0.05 loss and matched the loss reported a year ago. The company, however, beat revenue estimates for the quarter.

Why it matters — A OCGN watcher would care because the earnings miss versus analyst expectations and the revenue beat provide a clearer picture of the company's recent financial performance.

FAQ

Frequently asked questions about OCGN stock

What is the OCGN stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Ocugen, Inc. have a median 12-month price target of $11, with estimates ranging from $8 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OCGN stock a buy right now?

Of the 6 analysts covering Ocugen, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ocugen, Inc. 26 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OCGN?

As at 22 Aug 2026, Ocugen, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).

Will OCGN stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +672.1% from the last close, and Ticker Nerd's factor model ranks Ocugen, Inc. 26 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OCGN stock forecast for 2030?

No analyst covering Ocugen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $22 over the next 12 months.

How has OCGN stock performed over the past year?

Ocugen, Inc. returned +34.7% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ocugen, Inc. do?

Ocugen Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that address serious unmet medical needs.

What is the latest news on OCGN?

The most recent item we track (MarketBeat, 16 Aug 2026): "Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts". Ocugen is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration. CEO Shankar Musunuri discussed pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy during a Canaccord discussion.

Company

About Ocugen, Inc.

Ocugen Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that address serious unmet medical needs. The company’s core emphasis is on ophthalmology, particularly gene therapies for major blindness diseases using a modifier gene therapy platform and a gene-agnostic approach designed to target complex retinal disorders involving multiple gene networks. Key programs are aimed at inherited retinal diseases and age-related retinal conditions such as retinitis pigmentosa, Stargardt disease, and dry age-related macular degeneration. Beyond eye diseases, Ocugen is advancing regenerative cell therapies for orthopedic indications and inhaled mucosal vaccines intended for infectious disease prevention, including COVID-19 and seasonal influenza. Headquartered in Malvern, Pennsylvania and founded in 2013, Ocugen operates primarily in the United States and Ireland, serving global healthcare markets through partnerships, clinical development, and potential future commercialization of its pipeline. The company plays a specialized role in the biotechnology sector by targeting diseases with limited or no effective treatment options.

CEO Dr. Shankar Musunuri M.B.A., Ph.D. · 116 employees · United States · https://www.ocugen.com